A Novel Eight-Gene Signature for Lipid Metabolism Predicts the Progression of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma
- PMID: 37749448
- DOI: 10.1007/s43032-023-01364-z
A Novel Eight-Gene Signature for Lipid Metabolism Predicts the Progression of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma
Abstract
Recently, studies on the mechanisms underlying lipid metabolic reprogramming in cancer have increased. However, its significance in cervical cancer remains unclear. In the present study, a prognostic signature was constructed for patients with cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) using the expression profiles of lipid metabolism-related genes (LMRGs). Furthermore, using various bioinformatics methods, a prognostic gene signature was developed for progression-free survival (PFS). This signature was externally validated using a cervical cancer dataset (GSE44001). The characteristics of the molecular subgroups of LMRGs were analyzed, and target LMRGs were identified via differential gene analysis of the expression profiles and weighted gene correlation network analysis. Thereafter, the identified target genes were used to develop the prognostic gene signature using univariate, least absolute shrinkage and selection operator, and multivariate Cox regression analyses. The performance of the LMRG signature was evaluated using Kaplan-Meier curves, time-dependent receiver operating characteristic curves, decision curve analysis, mutation landscapes, gene set enrichment analysis, and immune score calculation. As a result, a novel eight-LMRG signature comprising ALDH3B2, CERS3, FA2H, GLTP, NR1H3, PLIN3, SLC44A3, and SQLE was constructed. Using this gene signature, patients with CESC and significantly distinguished PFS were divided. This eight-LMRG signature exhibited independent prognostic potential and superior predictive performance compared with a previously developed 12-gene signature. Our findings suggest that our novel eight-LMRG signature contributes to the implementation of precision medicine strategies for managing patients with cervical cancer by facilitating CESC prognosis.
Keywords: Cervical cancer; Gene signature; Lipid metabolism; Prognosis.
© 2023. The Author(s), under exclusive licence to Society for Reproductive Investigation.
Similar articles
-
Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.World J Surg Oncol. 2022 Oct 17;20(1):342. doi: 10.1186/s12957-022-02802-z. World J Surg Oncol. 2022. PMID: 36253777 Free PMC article.
-
Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.Front Immunol. 2022 Feb 10;13:783495. doi: 10.3389/fimmu.2022.783495. eCollection 2022. Front Immunol. 2022. PMID: 35222371 Free PMC article.
-
A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.Front Immunol. 2022 Jul 18;13:851622. doi: 10.3389/fimmu.2022.851622. eCollection 2022. Front Immunol. 2022. PMID: 35924232 Free PMC article.
-
A multi-omics-based investigation of the prognostic and immunological impact of necroptosis-related mRNA in patients with cervical squamous carcinoma and adenocarcinoma.Sci Rep. 2022 Oct 6;12(1):16773. doi: 10.1038/s41598-022-20566-0. Sci Rep. 2022. PMID: 36202899 Free PMC article. Clinical Trial.
-
Identification and Validation of the Anoikis-Related Gene Signature as a Novel Prognostic Model for Cervical Squamous Cell Carcinoma, Endocervical Adenocarcinoma, and Revelation Immune Infiltration.Medicina (Kaunas). 2023 Feb 13;59(2):358. doi: 10.3390/medicina59020358. Medicina (Kaunas). 2023. PMID: 36837559 Free PMC article.
Cited by
-
SQLE-a promising prognostic biomarker in cervical cancer: implications for tumor malignant behavior, cholesterol synthesis, epithelial-mesenchymal transition, and immune infiltration.BMC Cancer. 2024 Sep 11;24(1):1133. doi: 10.1186/s12885-024-12897-0. BMC Cancer. 2024. PMID: 39261819 Free PMC article.
-
Cancer metabolic reprogramming and precision medicine-current perspective.Front Pharmacol. 2024 Oct 17;15:1450441. doi: 10.3389/fphar.2024.1450441. eCollection 2024. Front Pharmacol. 2024. PMID: 39484162 Free PMC article. Review.
References
-
- Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 . - DOI - PubMed
-
- Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8:420–44. https://doi.org/10.1001/jamaoncol.2021.6987 .
-
- Arbyn M, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–203. https://doi.org/10.1016/S2214-109X(19)30482-6 . - DOI - PubMed
-
- Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila). 2012;5:18–23. https://doi.org/10.1158/1940-6207.CAPR-11-0542 . - DOI - PubMed
-
- Bernard HU, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70–9. https://doi.org/10.1016/j.virol.2010.02.002 . - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous